Related Experiment Videos
Bladder cancer genotype stability during clinical progression.
J L Tsao1, Y Yatabe, I D Markl
1Department of Pathology and Biochemistry, USC/Norris Comprehensive Cancer Center, University of Southern California, School of Medicine, Los Angeles, California, USA.
Genes, Chromosomes & Cancer
|August 5, 2000
Summary
Genomic instability in metastatic bladder cancer shows that most genetic changes accumulate before clinical presentation. Further loss of heterozygosity (LOH) events during disease progression are infrequent, indicating early accumulation of mutations.
Area of Science:
- Oncology
- Genetics
- Genomic Instability
Background:
- Genomic instability, characterized by extensive mutations, complicates tracking cancer progression.
- Estimating mutation accumulation rates requires serial comparisons, which are challenging.
- Understanding mutation dynamics during clinical progression is crucial for bladder cancer research.
Observation:
- Sequential cell lines from metastatic bladder cancer patients, isolated 6-11 months apart, were analyzed for loss of heterozygosity (LOH).
- Genomes were scanned at ~200 polymorphic microsatellite loci to enhance detection sensitivity.
- Both patients exhibited genomic instability, including aneuploidy and chromosomal instability.
Findings:
- Fractional allelic losses were 0.15 and 0.48, with over 90% genomic identity between initial and recurrent cell lines.
- Additional genetic changes during clinical progression were infrequent.
- Loss of heterozygosity events were not random but clustered on specific chromosomes.
Implications:
- The limited number of new LOH events suggests most allelic losses occur early in bladder cancer development.
- This finding implies that the majority of genomic alterations precede clinical manifestation.
- Further research into early-stage genomic events could reveal critical therapeutic targets.